Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS".

Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly CK, Zhu Y, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

ACS Med Chem Lett. 2017 Feb 24;8(3):377. doi: 10.1021/acsmedchemlett.7b00070. eCollection 2017 Mar 9.

2.

Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis.

Zhang Y, Zhao KT, Fox SG, Kim J, Kirsch DR, Ferrante RJ, Morimoto RI, Silverman RB.

J Med Chem. 2015 Aug 13;58(15):5942-9. doi: 10.1021/acs.jmedchem.5b00561. Epub 2015 Jul 31.

3.

Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties.

Xia G, Benmohamed R, Morimoto RI, Kirsch DR, Silverman RB.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5098-101. doi: 10.1016/j.bmcl.2014.08.066. Epub 2014 Sep 15.

4.

Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis.

Trippier PC, Zhao KT, Fox SG, Schiefer IT, Benmohamed R, Moran J, Kirsch DR, Morimoto RI, Silverman RB.

ACS Chem Neurosci. 2014 Sep 17;5(9):823-9. doi: 10.1021/cn500147v. Epub 2014 Jul 18.

5.

Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis.

Zhang Y, Benmohamed R, Huang H, Chen T, Voisine C, Morimoto RI, Kirsch DR, Silverman RB.

J Med Chem. 2013 Mar 28;56(6):2665-75. doi: 10.1021/jm400079a. Epub 2013 Mar 15.

6.

Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1.

Trippier PC, Benmohamed R, Kirsch DR, Silverman RB.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6647-50. doi: 10.1016/j.bmcl.2012.08.114. Epub 2012 Sep 7. Erratum in: Bioorg Med Chem Lett. 2014 Jan 15;24(2):691. Benmohammed, Radhia [corrected to Benmohamed, Radhia].

PMID:
23021992
7.

Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS.

Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly CK, Zhu Y, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

ACS Med Chem Lett. 2012 May 22;3(7):584-587. Erratum in: ACS Med Chem Lett. 2017 Feb 24;8(3):377.

8.

ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.

Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB.

J Med Chem. 2012 Jan 12;55(1):515-27. doi: 10.1021/jm2014277. Epub 2011 Dec 22.

PMID:
22191331
9.

Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells.

Zhang W, Benmohamed R, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

Bioorg Med Chem. 2012 Jan 15;20(2):1029-45. doi: 10.1016/j.bmc.2011.11.039. Epub 2011 Nov 30.

10.

Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.

Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

J Med Chem. 2011 Apr 14;54(7):2409-21. doi: 10.1021/jm101549k. Epub 2011 Mar 4.

11.

Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis.

Chen T, Benmohamed R, Arvanites AC, Ralay Ranaivo H, Morimoto RI, Ferrante RJ, Watterson DM, Kirsch DR, Silverman RB.

Bioorg Med Chem. 2011 Jan 1;19(1):613-22. doi: 10.1016/j.bmc.2010.10.052. Epub 2010 Oct 30.

12.

Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Benmohamed R, Arvanites AC, Kim J, Ferrante RJ, Silverman RB, Morimoto RI, Kirsch DR.

Amyotroph Lateral Scler. 2011 Mar;12(2):87-96. doi: 10.3109/17482968.2010.522586. Epub 2010 Nov 12.

PMID:
21073276
13.

A cell wall-active lipopeptide from the fungus Pochonia bulbillosa.

Koehn FE, Kirsch DR, Feng X, Janso J, Young M.

J Nat Prod. 2008 Dec;71(12):2045-8. doi: 10.1021/np800341u.

PMID:
19053516
14.
15.
16.

Biochemistry and molecular biology of sterol synthesis in Saccharomyces cerevisiae.

Lees ND, Bard M, Kirsch DR.

Crit Rev Biochem Mol Biol. 1999;34(1):33-47. Review. No abstract available.

PMID:
10090470
17.

Cell wall active antifungal compounds produced by the marine fungus Hypoxylon oceanicum LL-15G256. III. Biological properties of 15G256 gamma.

Albaugh D, Albert G, Bradford P, Cotter V, Froyd J, Gaughran J, Kirsch DR, Lai M, Rehnig A, Sieverding E, Silverman S.

J Antibiot (Tokyo). 1998 Mar;51(3):317-22.

18.
19.
20.

Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae--a review.

Lees ND, Skaggs B, Kirsch DR, Bard M.

Lipids. 1995 Mar;30(3):221-6. Review.

PMID:
7791529
21.

Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo.

Gaughran JP, Lai MH, Kirsch DR, Silverman SJ.

J Bacteriol. 1994 Sep;176(18):5857-60.

22.

The identification of a gene family in the Saccharomyces cerevisiae ergosterol biosynthesis pathway.

Lai MH, Bard M, Pierson CA, Alexander JF, Goebl M, Carter GT, Kirsch DR.

Gene. 1994 Mar 11;140(1):41-9.

PMID:
8125337
23.
24.

Mechanism-based screening for the discovery of novel antifungals.

Kirsch DR, DiDomenico BJ.

Biotechnology. 1994;26:177-221. Review. No abstract available.

PMID:
7749303
25.
26.

Brefeldin A causes a defect in secretion in Saccharomyces cerevisiae.

Vogel JP, Lee JN, Kirsch DR, Rose MD, Sztul ES.

J Biol Chem. 1993 Feb 15;268(5):3040-3.

27.

Dactylocyclines, novel tetracycline derivatives produced by a Dactylosporangium sp. I. Taxonomy, production, isolation and biological activity.

Wells JS, O'Sullivan J, Aklonis C, Ax HA, Tymiak AA, Kirsch DR, Trejo WH, Principe P.

J Antibiot (Tokyo). 1992 Dec;45(12):1892-8.

28.

Lanomycin and glucolanomycin, antifungal agents produced by Pycnidiophora dispersa. I. Discovery, isolation and biological activity.

O'Sullivan J, Phillipson DW, Kirsch DR, Fisher SM, Lai MH, Trejo WH.

J Antibiot (Tokyo). 1992 Mar;45(3):306-12.

29.
30.

The use of beta-galactosidase gene fusions to screen for antibacterial antibiotics.

Kirsch DR, Lai MH, McCullough J, Gillum AM.

J Antibiot (Tokyo). 1991 Feb;44(2):210-7.

31.

Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel of hypervirulent strain.

Whelan WL, Kirsch DR, Kwon-Chung KJ, Wahl SM, Smith PD.

J Infect Dis. 1990 Aug;162(2):513-8.

PMID:
1973698
32.

Cloning and characterization of the 2,3-oxidosqualene cyclase-coding gene of Candida albicans.

Kelly R, Miller SM, Lai MH, Kirsch DR.

Gene. 1990 Mar 15;87(2):177-83.

PMID:
2185141
33.

Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans.

Lai MH, Kirsch DR.

Nucleic Acids Res. 1989 Jan 25;17(2):804. No abstract available.

34.

Lysobactin, a novel antibacterial agent produced by Lysobacter sp. I. Taxonomy, isolation and partial characterization.

O'Sullivan J, McCullough JE, Tymiak AA, Kirsch DR, Trejo WH, Principe PA.

J Antibiot (Tokyo). 1988 Dec;41(12):1740-4.

35.
36.

Neoberninamycin, a new antibiotic produced by Micrococcus luteus.

Biskupiak JE, Meyers E, Gillum AM, Dean L, Trejo WH, Kirsch DR.

J Antibiot (Tokyo). 1988 May;41(5):684-7. No abstract available.

37.

The molecular genetics of Candida albicans.

Kurtz MB, Kirsch DR, Kelly R.

Microbiol Sci. 1988 Feb;5(2):58-63. Review.

PMID:
3079219
38.

Identification of macrotetrolide antibiotics in a screen to detect calcium channel blocking agents.

Biskupiak JE, Johnson JH, Forte M, Moreland S, Hedberg A, Brittain RJ, Christofalo BC, Geiger G, Kirsch DR.

J Antibiot (Tokyo). 1987 Nov;40(11):1653-6. No abstract available.

39.

Development of autonomously replicating plasmids for Candida albicans.

Kurtz MB, Cortelyou MW, Miller SM, Lai M, Kirsch DR.

Mol Cell Biol. 1987 Jan;7(1):209-17.

40.

Directed mutagenesis in Candida albicans: one-step gene disruption to isolate ura3 mutants.

Kelly R, Miller SM, Kurtz MB, Kirsch DR.

Mol Cell Biol. 1987 Jan;7(1):199-208.

41.

A modified screen for the detection of cell wall-acting antifungal compounds.

Kirsch DR, Lai MH.

J Antibiot (Tokyo). 1986 Nov;39(11):1620-2. No abstract available.

42.

Integrative transformation of Candida albicans, using a cloned Candida ADE2 gene.

Kurtz MB, Cortelyou MW, Kirsch DR.

Mol Cell Biol. 1986 Jan;6(1):142-9.

43.
45.

Molecular and genetic methods for studying mitosis and spindle proteins in Aspergillus nidulans.

Morris NR, Kirsch DR, Oakley BR.

Methods Cell Biol. 1982;25 Pt B:107-30. No abstract available.

PMID:
7050618
46.

Restriction endonuclease analysis and nucleotide composition of satellite III DNA from Drosophila virilis.

Kirsch DR, Cohen EH.

Biochem Biophys Res Commun. 1980 Oct 31;96(4):1603-9. No abstract available.

PMID:
6255946
47.

A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels.

Oakley BR, Kirsch DR, Morris NR.

Anal Biochem. 1980 Jul 1;105(2):361-3. No abstract available.

PMID:
6161559

Supplemental Content

Loading ...
Support Center